Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327911 · ClinicalTrials.gov registry record · Phase 1
Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)
A Phase 1 study, sponsored by Neurotech Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01327911: Completed Phase 1 study, sponsored by Neurotech Pharmaceuticals.
NCT01327911 is a Phase 1 study that has completed, run by Neurotech Pharmaceuticals. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01327911, a Phase 1 study, has completed, sponsored by Neurotech Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
Primary Outcome
Visual acuity decrease of \>=15 letters
Interventions
- BIOLOGICAL NT-501 implant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
What the finished NCT01327911 record still lists
NCT01327911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which NT-501 implant is the first listed.
NCT01327911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01327911 about?
NCT01327911 is a clinical study titled "Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)". This study is a phase 1, open label, non-randomized, multi-center, pilot study to evaluate the safety and tolerability of NT-501 implants in 5-7 study participants with Mactel.
What is the current status of trial NCT01327911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2011-05. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01327911?
The interventions under investigation include: NT-501 implant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01327911?
This trial is sponsored by Neurotech Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01327911's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia